ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2012
Uncovering undetected hypoglycemic events.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Evidence of traditional Chinese medicine for treating type 2 diabetes mellitus: from molecular mechanisms to clinical efficacy.Pharmaceutical biology · 2024Pooled it
- Using Natural Language Processing to Measure and Improve Quality of Diabetes Care: A Systematic Review.Journal of diabetes science and technology · 2021Pooled it
- The Effect of Insulin Degludec Versus Insulin Glargine U100 on Glucose Metrics Recorded During Continuous Glucose Monitoring in People With Type 1 Diabetes and Recurrent Nocturnal Severe Hypoglycemia.Journal of diabetes science and technology · 2025Trial
- HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea.Diabetologia · 2014 · on this mapTrial
- Trial
- Causal mediation pathways in continuous postprandial glucose monitoring for type 1 diabetes patients.npj metabolic health and disease · 2026Article
- Causal Mediation Pathways in Continuous Postprandial Glucose Monitoring for Type 1 Diabetes Patients.Research square · 2026Article
- Causal Mediation Pathways in Continuous Postprandial Glucose Monitoring for Type 1 Diabetes Patients.medRxiv : the preprint server for health sciences · 2026Article
- Continuous glucose monitoring, diabetes distress, and well-being in adults with type 1 diabetes: findings from a National Survey in Lithuania.Frontiers in clinical diabetes and healthcare · 2026Article
- Timing of Insulin Glargine 300 U/ML: Does It Really Matter in Terms of Efficacy and Safety at Insulin Initiation?Cureus · 2025Article
- Therapeutic errors involving diabetes medications reported to United States poison centers.Injury epidemiology · 2024Article
- GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?Current atherosclerosis reports · 2024Review
- Role of the Adrenal Medulla in Hypoglycaemia-Associated Autonomic Failure-A Diabetic Perspective.Metabolites · 2024Review
- Deep transfer learning and data augmentation improve glucose levels prediction in type 2 diabetes patients.NPJ digital medicine · 2021Article
- Differences between patients with type 1 diabetes with optimal and suboptimal glycaemic control: A real-world study of more than 30 000 patients in a US electronic health record database.Diabetes, obesity & metabolism · 2020Observational
- Comparison of the HAT study, the largest global hypoglycaemia study to date, with similar large real-world studies.Diabetes, obesity & metabolism · 2019Review
- Hypoglycemia incidence and awareness among insulin-treated patients with diabetes: the HAT study in Brazil.Diabetology & metabolic syndrome · 2018Article
- A Minimal Model Approach for Analyzing Continuous Glucose Monitoring in Type 2 Diabetes.Frontiers in physiology · 2018Article
- Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US.ClinicoEconomics and outcomes research : CEOR · 2017 · on this mapArticle
- Treatment of sulfonylurea and insulin overdose.British journal of clinical pharmacology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypoglycemia is the rate-limiting factor that often prevents patients with diabetes from safely and effectively achieving their glycemic goals. Recent studies have reported that severe hypoglycemia is associated with a significant increase in the adjusted risks of major macrovascular events, major microvascular events, and mortality. Minor hypoglycemic episodes can also have serious implications for patient health, psychological well being, and adherence to treatment regimens. Hypoglycemic events can impact the health economics of the patient, their employer, and third-party payers. Insulin treatment is a key predictor of hypoglycemia, with one large population-based study reporting an overall prevalence of 7.1% (type 1 diabetes mellitus) and 7.3% (type 2 diabetes mellitus) in insulin-treated patients, compared with 0.8% in patients with type 2 diabetes treated with an oral sulfonylurea. Patients with type 1 diabetes typically experience symptomatic hypoglycemia on average twice weekly and severe hypoglycemia once annually. The progressive loss of islet cell function in patients with type 2 diabetes results in a higher risk of both symptomatic and unrecognized hypoglycemia over time. Patients with diabetes who become hypoglycemic are also more susceptible to developing defective counter-regulation, also known as hypoglycemia awareness autonomic failure, which is life-threatening and must be aggressively addressed. In patients unable to recognize hypoglycemia symptoms, frequent home monitoring or use of continuous glucose sensors are critical. Primary care physicians play a key role in the prevention and management of hypoglycemia in patients with diabetes, particularly in those requiring intensive insulin therapy, yet physicians are often unaware of the multitude of consequences of hypoglycemia or how to deal with them. Careful monitoring, adherence to guidelines, and use of optimal treatment combinations are all important steps toward improving care in patients with diabetes. The most important goals are for primary care physicians to recognize that every patient treated with antihyperglycemic medications is at risk of iatrogenic hypoglycemia and to ask patients about hypoglycemia at every visit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.